0000950170-24-044836.txt : 20240416 0000950170-24-044836.hdr.sgml : 20240416 20240416165412 ACCESSION NUMBER: 0000950170-24-044836 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240401 FILED AS OF DATE: 20240416 DATE AS OF CHANGE: 20240416 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Weber Darin J. CENTRAL INDEX KEY: 0001936228 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40560 FILM NUMBER: 24848492 MAIL ADDRESS: STREET 1: C/O PROKIDNEY CORP. STREET 2: 3929 WESTPOINT BLVD., SUITE G CITY: WINSTON-SALEM STATE: NC ZIP: 27103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROKIDNEY CORP. CENTRAL INDEX KEY: 0001850270 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981586514 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2000 FRONTIS PLAZA BLVD. STREET 2: SUITE 250 CITY: WINSTON-SALEM STATE: NC ZIP: 27103 BUSINESS PHONE: 336-999-7028 MAIL ADDRESS: STREET 1: 2000 FRONTIS PLAZA BLVD. STREET 2: SUITE 250 CITY: WINSTON-SALEM STATE: NC ZIP: 27103 FORMER COMPANY: FORMER CONFORMED NAME: Social Capital Suvretta Holdings Corp. III DATE OF NAME CHANGE: 20210310 4 1 ownership.xml 4 X0508 4 2024-04-01 0001850270 PROKIDNEY CORP. PROK 0001936228 Weber Darin J. C/O PROKIDNEY CORP 2000 FRONTIS PLAZA BLVD, SUITE 250 WINSTON-SALEM NC 27103 false true false false SVP of Regulatory Development true Class A Ordinary Shares 2024-04-01 4 S false 300 1.69 D 273773 D Class A Ordinary Shares 2024-04-12 4 S false 84103 1.73 D 189670 D The reported sale of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2023. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.69 to $1.77, inclusive. The reporting person undertakes to provide to ProKidney Corp., any security holder of ProKidney Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Todd Girolamo as Attorney-in-Fact 2024-04-16